IKK is a complex composed of three subunits: IKKα, IKKβ, and IKKγ (also called NEMO).The complex serves as the center of signal integration for activating NF-B. In order to catalyze the phosphorylation of numerous I-B and NF-B proteins as well as other substrates, it combines signals from all NF-B activating stimuli. The IKKs IKK-alpha and IKK-beta, as well as the IKK-related kinases TBK1 and IKK-epsilon, make up the four members of the human IKK family.
The so-called canonical members, IKK-1 and IKK-2, phosphoryate I-B, activating the transcription factor NF-B, which in turn regulates the expression of several immunological and inflammatory genes. IRF3, a distinct substrate of the IKK-related proteins TBK-1 and IKK-epsilon, controls a separate set of genes, the byproducts of which include Type I interferons. Due to their critical roles in numerous biological processes, such as the immunological response, the stress response, and tumor growth, IKKs are a therapeutic target.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V82228 | Keap1-Nrf2-IN-7 | 2769963-42-8 | Keap1-Nrf2-IN-7 (compound 7v) is a potent Keap1-Nrf2 PPI (Keap1-Nrf2 protein-protein interaction) inhibitor (antagonist) with IC50 of 0.45 µM. |
|
V82225 | Keap1-Nrf2-IN-8 | 2769963-54-2 | Keap1-Nrf2-IN-8 (compound 12d) is a potent Keap1-Nrf2 PPI (Keap1-Nrf2 protein-protein interaction) inhibitor (antagonist) with IC50 of 64.5 nM and 14.2 nM in FP and TR-FRET assays, respectively. |
|
V0757 | LY2409881 trihydrochloride | 946518-60-1 | LY2409881trihydrochloride (LY-2409881; LY 2409881), thetrihydrochloride salt of LY-2409881, is a novel, potent and selective IKK2 (IκB kinase β) inhibitor with potential anticancer and anti-inflammatory activity. |
|
V0762 | Mesalamine (5ASA; 5-aminosalicylic acid; Asacol; mesalazine; 5-ASA) | 89-57-6 | Mesalamine (also named as5ASA; Z-206; AJG-501; MAX-002; 5-aminosalicylic acid; Asacol;mesalazine; 5-ASA) is a specific and orally bioavailableinhibitor of TNFα-induced IKK activity with potential anti-inflammatory activity. |
|
V4027 | MLN120B | 783348-36-7 | MLN120B (MLN-120B) is a novel, potent, specific and ATP competitiveIKKβ (IκB kinase beta subunit) inhibitor with anti-inflammatory activity. |
|
V2438 | NF-κB-IN-1 | 1227098-15-8 | NF-κB-IN-1, a 4-arylene curcumin analog, is a potent inhibitor of the NF-κB signaling pathway. |
|
V0753 | PS-1145 | 431898-65-6 | PS-1145 (PS1145) is a novel, potent and specific IKK (IκB kinase) inhibitor with anticancer activity. |
|
V82226 | Resolvin D1-d5 (RvD1-d5) | 1881277-32-2 | Resolvin D1-d5 is the deuterium labelled form of Resolvin D1. |
|
V0761 | SC-514 | 354812-17-2 | SC-514 (SC 514; SC514) is a novel, potent, orally bioactive, selective and reversible, and ATP-competitive IKK-2 inhibitor with potential anti-inflammatory activity. |
|
V51258 | TBK1-IN-1 | TANK binding kinase 1 (TBK1) inhibitor | |
|
V51260 | TBK1/IKKε-IN-1 | 2058264-32-5 | dual TBK1 and IKKε inhibitor |
|
V3366 | TBK1/IKKε-IN-1 | 1292310-49-6 | TBK1/IKKε-IN-1 is a novel, potent dualTBK1andIKKεinhibitor with potential anticancer activity. |
|
V32070 | TBK1/IKKε-IN-5 | 1893397-65-3 | TBK1/IKKε-IN-5 (compound 1 in patent WO 2016049211) is a potent dual TBK1 and IKKε inhibitor, with IC50 of 1 nM and 5.6 nM for TBK1 and IKKε, respectively. |
|
V51259 | TBK1/IKKε-IN-6 | 2306877-20-1 | dual TBK1 and IKKε inhibitor |
|
V0751 | TPCA-1 (GW-683965; GW683965) | 507475-17-4 | TPCA-1 (also known as TPCA1; GW-683965; GW683965)is novel, potent, and selective inhibitor of IKK-2 with potential anti-inflammatory activity. |
|
V0758 | WS3 | 1421227-52-2 | WS-3 (WS3; WS 3) is a novel and potent small molecule modulatior of Erb3 binding protein-1 (EBP1) and the IκB (IkappaB) kinase with important biological activity. |
|
V0759 | WS6 | 1421227-53-3 | WS6 (WS6; WS 6) is a novel and potent small molecule modulator of β cell proliferation via modulation of Erb3 binding protein-1 (EBP1) and the IκB kinase pathway with important biological activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
